CN114430744B - 抗Tau抗体及其用途 - Google Patents
抗Tau抗体及其用途 Download PDFInfo
- Publication number
- CN114430744B CN114430744B CN202080063893.8A CN202080063893A CN114430744B CN 114430744 B CN114430744 B CN 114430744B CN 202080063893 A CN202080063893 A CN 202080063893A CN 114430744 B CN114430744 B CN 114430744B
- Authority
- CN
- China
- Prior art keywords
- tau
- antibody
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2019-0085233 | 2019-07-15 | ||
| KR20190085233 | 2019-07-15 | ||
| PCT/KR2020/009207 WO2021010712A1 (ko) | 2019-07-15 | 2020-07-13 | 항-타우 항체 및 이의 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114430744A CN114430744A (zh) | 2022-05-03 |
| CN114430744B true CN114430744B (zh) | 2024-06-21 |
Family
ID=74088428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080063893.8A Active CN114430744B (zh) | 2019-07-15 | 2020-07-13 | 抗Tau抗体及其用途 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220204601A1 (enExample) |
| EP (1) | EP4001305B1 (enExample) |
| JP (1) | JP7595061B2 (enExample) |
| KR (1) | KR102196840B1 (enExample) |
| CN (1) | CN114430744B (enExample) |
| AU (1) | AU2020313751A1 (enExample) |
| BR (1) | BR112022000719A2 (enExample) |
| CA (1) | CA3143811A1 (enExample) |
| CL (1) | CL2022000087A1 (enExample) |
| GB (1) | GB2600599B (enExample) |
| IL (1) | IL289813A (enExample) |
| MX (1) | MX2022000603A (enExample) |
| MY (1) | MY207132A (enExample) |
| PH (1) | PH12022550106A1 (enExample) |
| WO (1) | WO2021010712A1 (enExample) |
| ZA (1) | ZA202200724B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014165271A2 (en) | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
| MX2018013384A (es) | 2016-05-02 | 2019-02-28 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| EP3452507B1 (en) | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
| SG11201910066QA (en) | 2017-05-02 | 2019-11-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| TWI859197B (zh) | 2019-03-03 | 2024-10-21 | 愛爾蘭商普羅帝納生物科學公司 | 識別ｔａｕ之抗體 |
| WO2023039456A1 (en) * | 2021-09-09 | 2023-03-16 | The University Of North Carolina At Chapel Hill | Monoclonal antibodies targeting acetylated tau and methods of use thereof |
| EP4405680A1 (en) | 2021-09-20 | 2024-07-31 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
| KR20250010000A (ko) * | 2022-05-27 | 2025-01-20 | 주식회사 진큐어 | 신규 펩타이드 및 그의 용도 |
| CN115724967A (zh) * | 2022-09-21 | 2023-03-03 | 天津鸿宇泰生物科技有限公司 | 一种识别Tau蛋白N端区域的单克隆抗体及其应用 |
| JP2025540336A (ja) * | 2022-12-08 | 2025-12-11 | アデル，インク | 抗タウ抗体及びペプチドを含む融合体とその用途 |
| WO2024133723A1 (en) | 2022-12-22 | 2024-06-27 | Institut National de la Santé et de la Recherche Médicale | Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy |
| CN116716352A (zh) * | 2023-05-16 | 2023-09-08 | 深圳湾实验室 | Tau蛋白聚集的细胞模型、其构建方法及应用 |
| CN116693682B (zh) * | 2023-06-02 | 2024-04-19 | 涌源合生科技(深圳)有限公司 | 抗Tau蛋白抗体及其制备方法和用途 |
| CN116948025B (zh) * | 2023-09-14 | 2024-04-02 | 北京凯祥弘康生物科技有限公司 | 一种抗Tau蛋白的抗体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130251731A1 (en) | 2012-03-22 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies |
| CA2869438C (en) * | 2012-04-05 | 2021-08-17 | Ac Immune S.A. | Humanized tau antibody |
| EP2870176A4 (en) | 2012-07-03 | 2016-09-28 | Univ Washington | ANTIBODIES DIRECTED AGAINST TAU |
| TWI734975B (zh) * | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| AR103713A1 (es) * | 2015-02-26 | 2017-05-31 | Lilly Co Eli | Anticuerpos contra tau y sus usos |
| WO2018106889A1 (en) * | 2016-12-09 | 2018-06-14 | Cogwellin L.L.C. | Diagnosis of alzheimer's disease |
| WO2018117647A1 (ko) * | 2016-12-21 | 2018-06-28 | 주식회사 아델 | 변이된 타우 단백질 단편 및 이의 용도 |
-
2020
- 2020-07-13 BR BR112022000719A patent/BR112022000719A2/pt unknown
- 2020-07-13 WO PCT/KR2020/009207 patent/WO2021010712A1/ko not_active Ceased
- 2020-07-13 GB GB2201160.5A patent/GB2600599B/en active Active
- 2020-07-13 JP JP2022503414A patent/JP7595061B2/ja active Active
- 2020-07-13 CA CA3143811A patent/CA3143811A1/en active Pending
- 2020-07-13 MY MYPI2022000234A patent/MY207132A/en unknown
- 2020-07-13 EP EP20841174.4A patent/EP4001305B1/en active Active
- 2020-07-13 AU AU2020313751A patent/AU2020313751A1/en active Pending
- 2020-07-13 MX MX2022000603A patent/MX2022000603A/es unknown
- 2020-07-13 KR KR1020200086341A patent/KR102196840B1/ko active Active
- 2020-07-13 CN CN202080063893.8A patent/CN114430744B/zh active Active
- 2020-07-13 PH PH1/2022/550106A patent/PH12022550106A1/en unknown
-
2022
- 2022-01-12 US US17/574,227 patent/US20220204601A1/en active Pending
- 2022-01-12 CL CL2022000087A patent/CL2022000087A1/es unknown
- 2022-01-12 IL IL289813A patent/IL289813A/en unknown
- 2022-01-14 ZA ZA2022/00724A patent/ZA202200724B/en unknown
Non-Patent Citations (2)
| Title |
|---|
| Acetylated tau, a novel pathological signature in Alzheimer’s disease and other tauopathies;David J. Irwin et al.;Brain;第135卷;第807-818页 * |
| P-tau 蛋白在颅脑损伤及相关神经退行性病中的研究进展;李瑞力;医学研究生学报;第30卷(第8期);第889-892页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL289813A (en) | 2022-03-01 |
| CN114430744A (zh) | 2022-05-03 |
| MY207132A (en) | 2025-01-31 |
| EP4001305A1 (en) | 2022-05-25 |
| GB202201160D0 (en) | 2022-03-16 |
| GB2600599B (en) | 2025-05-21 |
| WO2021010712A1 (ko) | 2021-01-21 |
| CA3143811A1 (en) | 2021-01-21 |
| JP2022541539A (ja) | 2022-09-26 |
| TW202116801A (zh) | 2021-05-01 |
| AU2020313751A1 (en) | 2022-02-10 |
| US20220204601A1 (en) | 2022-06-30 |
| KR102196840B1 (ko) | 2020-12-30 |
| BR112022000719A2 (pt) | 2022-03-29 |
| EP4001305B1 (en) | 2026-07-01 |
| EP4001305A9 (en) | 2023-05-24 |
| ZA202200724B (en) | 2026-04-29 |
| JP7595061B2 (ja) | 2024-12-05 |
| GB2600599A8 (en) | 2024-12-25 |
| PH12022550106A1 (en) | 2022-11-21 |
| EP4001305A4 (en) | 2022-10-12 |
| CL2022000087A1 (es) | 2023-03-10 |
| GB2600599A (en) | 2022-05-04 |
| MX2022000603A (es) | 2022-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7595061B2 (ja) | 抗タウ抗体およびその使用 | |
| TWI681972B (zh) | 抗免疫原性醣肽之抗體，包含彼等之組合物及其用途 | |
| EP3160999B1 (en) | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau | |
| JP5795833B2 (ja) | スフィンゴシン−１−リン酸と結合させるための組成物および方法 | |
| JP5732182B2 (ja) | 眼疾患と症状を処置するための組成物および方法 | |
| KR102472683B1 (ko) | 녹내장의 치료를 위한 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체의 용도 | |
| KR102866306B1 (ko) | 신경 성장 인자에 대한 단일 클론 항체, 및 이의 코딩 유전자 및 용도 | |
| IL263530B2 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| AU2017384681A1 (en) | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation | |
| KR20190083356A (ko) | 시누클레인병증의 치료를 위한 제제, 용도 및 방법 | |
| CN104602708A (zh) | 痴呆症治疗药或预防药 | |
| JP2018139530A (ja) | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 | |
| JP6952888B2 (ja) | 抗ｐａｃａｐ抗体 | |
| EA039554B1 (ru) | Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости | |
| WO2023206609A1 (zh) | 针对p-tau 217的抗体及其用途 | |
| US11434281B2 (en) | Monoclonal antibodies targeting PHF1 and AT8 epitopes of human tau protein | |
| WO2020261281A1 (en) | Semaphorin 3a antibodies and uses thereof | |
| EP4206229A1 (en) | A binding molecule able to neutralize proxi protein | |
| EA047253B1 (ru) | Антитело к тау-белку и его применение | |
| IL294932A (en) | Anti-ide antibodies and uses of same | |
| JP7862799B2 (ja) | 抗ｌｒｐ１抗体を含む視神経保護剤 | |
| CN113603773A (zh) | 靶向淀粉样蛋白的单克隆抗体7b8、分泌该抗体的杂交瘤细胞株及应用 | |
| EA044828B1 (ru) | Моноклональное антитело против фактора роста нервов, кодирующий его ген и его применение | |
| EA045151B1 (ru) | Антитела анти-phf-тау и их применение | |
| HK1210031B (en) | Therapeutic agent or prophylactic agent for dementia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |